Skip to main content

Healthy Chinese Volunteers

3
Pipeline Programs
4
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Biomed
BiomedAustralia - Sydney
1 program
1
HBM9161Phase 11 trial
Active Trials
NCT03971916Completed24Est. Nov 2019
Harbour BioMed
Harbour BioMedChina - Shanghai
1 program
1
HBM9161Phase 1
TaiGen Biotechnology
TaiGen BiotechnologyChina - Beijing
1 program
1
TG-1000Phase 11 trial
Active Trials
NCT04495322Completed66Est. Dec 2020
Lee's Pharmaceutical
Lee's PharmaceuticalChina - Guangzhou
1 program
TecarfarinPHASE_11 trial
Active Trials
NCT04627116Unknown40Est. Dec 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
TaiGen BiotechnologyTG-1000
Lee's PharmaceuticalTecarfarin
BiomedHBM9161

Clinical Trials (3)

Total enrollment: 130 patients across 3 trials

NCT04495322TaiGen BiotechnologyTG-1000

To Evaluate the Safety, Tolerability, and Pharmacokinetics Profiles of TG-1000 in Healthy Volunteers, and the Food Effect on Pharmacokinetics of Single Oral Dose of TG-1000 in Healthy Volunteers.

Start: Jul 2020Est. completion: Dec 202066 patients
Phase 1Completed
NCT04627116Lee's PharmaceuticalTecarfarin

An Ascending, Multiple-Dose, Safety and Tolerability Study of Tecarfarin in Healthy Chinese Volunteers

Start: Apr 2020Est. completion: Dec 202040 patients
Phase 1Unknown
NCT03971916BiomedHBM9161

A Phase I Study Evaluating the Safety, Tolerability, PK and PD in Healthy Chinese Volunteers

Start: Jun 2019Est. completion: Nov 201924 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.